
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21655361</article-id><article-id pub-id-type="pmc">3108901</article-id><article-id pub-id-type="publisher-id">158</article-id><article-id pub-id-type="publisher-id">2010MOLVIS0593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>PAX6</italic> gene analysis in irido-fundal coloboma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Kishlay</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tanwar</surname><given-names>Mukesh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Naithani</surname><given-names>Prashant</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Insaan</surname><given-names>Rajpal</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garg</surname><given-names>Satpal</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Venkatesh</surname><given-names>Pradeep</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dada</surname><given-names>Rima</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Laboratory For Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India</aff><aff id="aff2"><label>2</label>Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India</aff></contrib-group><author-notes><fn><p>The first two authors contributed equally to the work</p></fn><corresp id="cor1">Correspondence to: Dr. Rima Dada, Additional Professor, Laboratory For Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India-110029; Phone: +91-11-26546716; FAX: +91-11-26588663; email: <email xlink:href="rima_dada@rediffmail.com">rima_dada@rediffmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2011</year></pub-date><volume>17</volume><fpage>1414</fpage><lpage>1419</lpage><history><date date-type="received"><day>29</day><month>12</month><year>2010</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Molecular Vision.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the
        Creative Commons Attribution License, which permits unrestricted use,
        distribution, and reproduction in any medium, provided the original
        work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To screen the paired box gene 6 (<italic>PAX6</italic>) gene in irido-fundal coloboma.</p></sec><sec><title>Methods</title><p>The entire coding region of <italic>PAX6</italic> including intron-exon boundaries was amplified from cases (n=30) and controls (n=30). All sequences were analyzed against the ensemble sequence (ENSG00000007372) for <italic>PAX6</italic>.</p></sec><sec><title>Results</title><p>DNA sequence analysis of patients and controls revealed a total of three nucleotide changes (g.31815391Cytosine&#x0003e;Thymine; Glycine72Glycine and g.31812215Thymine&#x0003e;Guanine) of which one was neutral/synonymous change and the remaining two were intronic changes. Of these 3 changes, 2 were novel and one was already reported change. All these changes were non-pathogenic, according to in silico analysis.</p></sec><sec><title>Conclusions</title><p>In our study no pathogenic <italic>PAX6</italic> mutation were identified. This suggests involvement of other coloboma genes. This study expands the SNP spectrum of <italic>PAX6</italic>, only rare variations which are not causative have been found. Since this is a pilot study in the north Indian population, results should be confirmed in different populations by similar studies. Familial cases are required for determining the underlying genetic loci accounting for this clinical phenotype and may lead to better understanding of disease pathogenesis.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Dada</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Congenital malformations of the eyeball appear to occur more frequently in certain countries like India and Sri Lanka, accounting for approximately 25% of cases of visual impairment and blindness [<xref ref-type="bibr" rid="r1">1</xref>]. Ocular coloboma is a congenital, common, and heterogeneous malformation which includes a spectrum of anomalies ranging from iris coloboma to clinical anophthalmos. Ocular coloboma, as an isolated defect, is usually inherited as an autosomal dominant disorder, although autosomal recessive inheritance also occurs. Coloboma is a hole in one of the structures of the eye, such as the iris, retina, choroid, or optic disc. If coloboma is present both in iris and retina it is known as irido-fundal coloboma. According to coloboma location in the retina and whether it involves the optic nerve or not, coloboma is classified into six types by Gopal [<xref ref-type="bibr" rid="r2">2</xref>]: (I) this involves the optic nerve and is the biggest type of coloboma (<xref ref-type="fig" rid="f1">Figure 1</xref>). Vision is generally quite poor in this type; (II) involves the optic nerve but it is smaller than type I, so vision is poor but not as bad as in type I coloboma; (III) this just misses the optic nerve (<xref ref-type="fig" rid="f2">Figure 2</xref>) so vision can be quite good. However if associated with increased axial length and resulting high myopic refractive error (spectacle number) the vision can be decreased; (IV) this coloboma involves only the optic nerve but not much retina that surrounds it. Vision can be good to average depending on how much the optic nerve is distorted; (V) this coloboma is in the periphery and does not involve the optic nerve as well as the main area of the retina (<xref ref-type="fig" rid="f3">Figure 3</xref>). As far as vision is considered it is quite good in this type and any problem in vision might not be noticed by the patient; (VI) these are partially aborted attempts at forming coloboma. Vision is unaffected in this type of coloboma.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Fundus photograph in type I coloboma.</p></caption><graphic xlink:href="mv-v17-1414-f1"/></fig><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Fundus photograph in type III coloboma.</p></caption><graphic xlink:href="mv-v17-1414-f2"/></fig><fig id="f3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Fundus photograph in type V coloboma.</p></caption><graphic xlink:href="mv-v17-1414-f3"/></fig><p>The estimated prevalence of coloboma is 1 in 10,000 in the world population [<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r4">4</xref>]. Coloboma associated with other syndromes may cause up to 10% of the childhood blindness [<xref ref-type="bibr" rid="r5">5</xref>]. The genetic basis of coloboma remains elusive. Recent studies suggest that earlier developmental processes in eye are controlled by a complex network of transcriptional factors, cell cycle regulators and diffusible signaling molecules [<xref ref-type="bibr" rid="r6">6</xref>].</p><p>Paired box gene 6 (<italic>PAX6</italic>), a member of the paired box family of transcription factors, has been identified as a key regulator of eye development in both vertebrates and invertebrates [<xref ref-type="bibr" rid="r7">7</xref>-<xref ref-type="bibr" rid="r9">9</xref>]. During early mouse eye development, expression of Pax6 has been shown in the presumptive lens ectoderm, lens placode, lens vesicle and optic vesicle [<xref ref-type="bibr" rid="r10">10</xref>,<xref ref-type="bibr" rid="r11">11</xref>]. At later stages, Pax6 is found in epithelia of conjunctiva, cornea, lens, and ciliary body and in the neural retina [<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r13">13</xref>]. In humans, mutations in <italic>PAX6</italic> have been demonstrated in several patients with aniridia [<xref ref-type="bibr" rid="r14">14</xref>-<xref ref-type="bibr" rid="r17">17</xref>], a panocular disease that is associated with iris hypoplasia, corneal opacification, cataract, foveal dysplasia, and other diseases [<xref ref-type="bibr" rid="r18">18</xref>].</p><p><italic>PAX6</italic> is located on chromosome 11p13 acts as transcriptional regulator of other genes that are associated with coloboma. This gene contains 14 exons and encodes a 422-amino acid polypeptide containing two DNA-binding domains, a bipartite paired domain, and a paired type homeodomain [<xref ref-type="bibr" rid="r19">19</xref>]. The paired domain, which is coded by exons 5&#x02013;7 of <italic>PAX6</italic>, has two subdomains: the relatively conserved 74-amino acid NH<sub>2</sub>-terminal sub-domain and the more divergent 54-amino acid COOH-terminal subdomain. The latter sub-domain is a common place for mutations [<xref ref-type="bibr" rid="r19">19</xref>,<xref ref-type="bibr" rid="r20">20</xref>]. Currently there are around 500 mutations that have been reported (Human PAX6 Allelic Variant Database (<ext-link ext-link-type="uri" xlink:href="http://pax6.hgu.mrc.ac.uk/">HPAVD</ext-link>). Most <italic>PAX6</italic> nonsense mutations lead to aniridia, while missense mutations are related to foveal hypoplasia, congenital cataracts, or anterior segment anomalies [<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r22">22</xref>].</p><p>In this preliminary pilot study we have screened <italic>PAX6</italic> for mutations in irido-fundal coloboma patients (n=30) and normal healthy controls (n=30).</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient selection and DNA isolation</title><p>The research followed the tenets of the Declaration of Helsinki in the treatment of the subject reported herein. The study was approved by institutional review board (IRB # IRB00006862) of All India Institute of Medical Sciences (AIIMS) and all participants gave their written informed consent. A total of thirty coloboma patients presented at the Dr. R. P. Centre for Ophthalmic Sciences (AIIMS, New Delhi, India) were enrolled in this study. Clinical evaluation involved fundoscopy (direct and indirect ophthalmoscopy), slitlamp-biomicroscopy, and retinoscopy. Of these patients, 18 were males and 12 were females. Mean age of presentation was 16.32 years. Diagnosis of coloboma involved the presence of deficient of iris tissue and presence of coloboma in retina on clinical examination. All cases were sporadic without any family history. All cases secondary to causes like trauma etc. were excluded from the study.</p><p>After informed consent, detailed personal, medical, and occupational history was collected and a family tree up to three generations was drawn. Thirty ethnically matched normal individuals without any ocular disorder were enrolled as controls. Health information was obtained from controls through the questionnaire; all underwent ophthalmological examination and a blood sample (5&#x000a0;ml) was collected in EDTA (EDTA) vacutainers (Greiner&#x000a0;Bio-One, GmbH, Frickenhausen, German<bold>y</bold>) from patients and controls for DNA extraction. DNA was extracted from whole blood samples of all patients and controls using the phenol-chloroform method.</p></sec><sec><title>Polymerase chain reaction (PCR) and DNA Sequencing</title><p>All coding regions of <italic>PAX6</italic> including exon-intron junctions were amplified using a set of eight oligonucleotide primers (<xref ref-type="table" rid="t1">Table 1</xref>). These primers were designed using NCBI <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/">PRIMER3</ext-link> program.</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Primers used for <italic>PAX6</italic> amplification.</title></caption><table frame="hsides" rules="groups"><col width="51" span="1"/><col width="212" span="1"/><col width="212" span="1"/><col width="64" span="1"/><col width="63" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Sample number</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Forward primer sequence (5&#x02032;-3&#x02032;)</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Reverse primer sequence (5&#x02032;-3&#x02032;)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Product size (bp)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Annealing temp (&#x000b0;C)</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAGTTCAGGCCTACCTGATGCAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGAAGAGCCAAGCAAACGCCCTC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">313<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CGCCGAGGTTGGCACAGGTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCATGGGCTGGGGAGAGCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">710<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CGTTTTGATGCATCTTCAGGCAGTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGGCATTCCTCTCTGTTCCCCCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">703<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGTGAAGGACCCCCTCCGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ACACACACGCACCCACCAGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">647<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">61<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ACCAGGCCCCTTTTGGAGGCT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGCATTCAGTGACCTTTCTGTGGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">554<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAGTGGGGAGGTGGGAACCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGGCCCTGAGCCACTCCTCAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">837<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCTGTGGCCAGTGGAAGGAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGGCCCCCTACTGAGCTTCG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">636<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">TCCTTTGGATTGGGGTGGGGG</td><td valign="top" align="left" rowspan="1" colspan="1">CGTGGCAAAGCTTGTTGATCATGG</td><td valign="top" align="center" rowspan="1" colspan="1">713</td><td valign="top" align="center" rowspan="1" colspan="1">62</td></tr></tbody></table></table-wrap><p>Each reaction was performed in a 25&#x000a0;&#x000b5;l mixture containing 0.2&#x000a0;&#x000b5;M each primer, 0.5 U Taq DNA polymerase, 2.5&#x000a0;&#x000b5;l of 10&#x000d7; PCR buffer (Biogene, New Delhi, India) with 2.5&#x000a0;mM MgCl<sub>2</sub>, and approximately 100 ng genomic DNA. PCR was performed in thermal cycler (My Cycler; BioRad, Gurgaon, India) under the conditions shown in <xref ref-type="table" rid="t1">Table 1</xref>.</p><p>All PCR products were analyzed on 1.8% agarose gel stained with ethidium-bromide (EtBr; 10&#x000a0;mg/ml). Agarose gels were analyzed using the Gel Documentation System (Applied Biosystems, Carlsbad, CA). Amplified PCR products were purified using gel/PCR DNA fragments extraction kit (Catalog number DF100; Geneaid Biotech Ltd., Sijhih City, Taiwan). Purified PCR products were outsourced for sequencing at Molecular Cloning Laboratories (<ext-link ext-link-type="uri" xlink:href="http://www.mclab.com/product.php?productid=19071">MCLAB</ext-link>, South San Francisco, CA).</p><p>DNA sequences were compared with the human <ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/Homo_sapiens/Gene/Sequence?g=ENSG00000007372;r=11%3A31806340-31839509">PAX6</ext-link> reference sequence.</p></sec><sec><title>Insilico analysis for predicting pathogenicity of mutations</title><p>An <ext-link ext-link-type="uri" xlink:href="http://www.fruitfly.org/seq_tools/splice.html">improved splice site predictor tool</ext-link> [<xref ref-type="bibr" rid="r23">23</xref>] was used for predicting the effect of an intronic nucleotide change on splicing of <italic>PAX6</italic> mRNA.</p></sec></sec><sec sec-type="results"><title>Results</title><p>DNA sequence analysis of patients and controls revealed a total of three nucleotide changes. Of which one was neutral/synonymous and novel change. The remaining two changes were intronic, one of which was novel. Details of these cases are tabulated (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Clinical manifestations of cases with irido-fundal coloboma.</title></caption><table frame="hsides" rules="groups"><col width="47" span="1"/><col width="46" span="1"/><col width="28" span="1"/><col width="120" span="1"/><col width="77" span="1"/><col width="80" span="1"/><col width="103" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Patient ID</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Age (years)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Sex</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Iridofundla coloboma type</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Axial length (RE;LE)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Visual acuity (RE;LE)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Treatment</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L Type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21.62;21.59<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3/60; 3/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/LType I IFC + microophthalmia +microcornea + nystagamus<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24.26;25.50<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2/60; 1/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Laser not possible due to extreme microcornea<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">LE Inferonasal + IFC type III<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20.64;20.33<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/6; PL +ve<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">LE laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC type I<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19.25;22.20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">PL+; PL +ve<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">No laser done<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L microophthalmia +microcornea + nystagamus + type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20.21;20.85<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/60;1/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">No laser done due to extreme microcornea<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L Nystagymus + type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26.22; 22.71<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">FCCF;FCCF<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE IFC type II + amblyopia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24.81;22.69<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">FCCF;6/12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">LE type III IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22.84;21.77<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/6; 6/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">L/E laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE IFC type III<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26.11;22.60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/24; 6/6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC type I<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24.50;24.60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/60;2/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC11<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE IFC type III<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21.54;20.70<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Patient non-cooperative<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE IFC; L Iris coloboma; B/L microcornea<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20.01; 20.39<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">FCCF;6/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC13<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L (microophthalmia +microcornea + distichiasis + IFC type I<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20.08;22.00<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">FCCF;1/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC14<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE IFC type II coloboma<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25.25;23.50<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">HMCF/6/24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">R/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21.91/21.02<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/60; 6/36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC16<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L microophthalmia + type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22.65;21.80<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3/60;6/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC17<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L type I IFC with squint<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18.25; 22.45<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/60; 2/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L microophthalmia + IFC type I<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22.45; 23.10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">PL+; 1/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L microcornea + type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22.12; 22.70<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/60; 3/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC type III + nystagamus<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26.18; 27.66<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">HMCF/6/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC21<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">LE IFC type II<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22.73; 26.73<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/6; HMCF<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC22<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC type III<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21.35; 21.50<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/36; 6/36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC23<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC type IV<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24.09; 24.24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/60; 1/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC type IV + microcornea + nystagymous<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29.55; 24.99<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">HMCF; FC2M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE type I IFC; LE type V IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26.81; 23.71<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">HMCF/6/6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC26<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L type III IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24.35; 24.50<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/18, 6/18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC27<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L IFC Type I<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26.25; 25.90<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/60; 2/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC28<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">LE type III IFC + Microcornea<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22.50; 22.24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/6;6/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">LE laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC29<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">RE IFC type III; LE type II IFC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24.45; 25.50<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/60; 2/60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IFC30</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">M</td><td valign="top" align="center" rowspan="1" colspan="1">B/L type V IFC</td><td valign="top" align="center" rowspan="1" colspan="1">23.50;22.80</td><td valign="top" align="center" rowspan="1" colspan="1">6/9; 6/12</td><td valign="top" align="center" rowspan="1" colspan="1">B/L laser</td></tr></tbody></table><table-wrap-foot><p>Key: IFC represents Iridofundal coloboma; LE represents Left eye; RE represents Right eye; FCCF represents Finger counting close to face; HMCF represents Hand motion close to face; PL represents Perception of light.</p></table-wrap-foot></table-wrap><sec><title>g.31815391Cytosine&#x0003e;Thymine</title><p>A novel single nucleotide change from cytosine (C) to thymine (T) at genomic position g. 31815391 (<xref ref-type="fig" rid="f4">Figure 4</xref>) was present in one case but absent in controls. The alteration is located in intron 9 (IVS9+40). This change was registered at GenBank with accession number <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/HQ397715">HQ397715</ext-link>.</p><fig id="f4" fig-type="figure" position="float"><label>Figure 4</label><caption><p>DNA sequence of <italic>PAX6</italic> equivalent to g.31815399 to 31815385. <bold>A</bold>: The reference sequence derived from the control is shown. <bold>B</bold>: The sequence derived from patient shows a heterozygous C&#x0003e;T mutation at g.31815391.</p></caption><graphic xlink:href="mv-v17-1414-f4"/></fig></sec><sec><title>g.31823250 Thymine&#x0003e;Guanine</title><p>In this mutation a single nucleotide T was replaced by guanine (G) at genomic position g.31823250; cDNA position c.216; codon 72 resulted in a codon change GGT&#x0003e;GGG which predicts a synonymous change p.Gly72Gly (p.G72G; <xref ref-type="fig" rid="f5">Figure 5</xref>). This change was present as heterozygous change in 29 cases and 20 controls; and as a homozygous change in one case. This change was novel and registered at GenBank with accession number <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/HQ397714">HQ397714</ext-link>.</p><fig id="f5" fig-type="figure" position="float"><label>Figure 5</label><caption><p>DNA sequence of <italic>PAX6</italic> equivalent to codon 71&#x02013;75. <bold>A</bold>: The reference sequence derived from the control shows the heterozygous c.216T&#x0003e;G change which predicts a codon change from GGT&#x0003e;GGG and p.G72G mutation. <bold>B</bold>: The sequence derived from another patient shows a homozygous p.G72G mutation.</p></caption><graphic xlink:href="mv-v17-1414-f5"/></fig></sec><sec><title>g.31812215Thymine&#x0003e;Guanine</title><p>A single nucleotide change from T to G at genomic position g.31812215 (<xref ref-type="fig" rid="f6">Figure 6</xref>) was present in six cases and one control. The alteration is located in intron 12 (IVS13&#x02013;42).</p><fig id="f6" fig-type="figure" position="float"><label>Figure 6</label><caption><p>DNA sequence of <italic>PAX6</italic> equivalent to g.31812220 to 31812209. <bold>A</bold>: The reference sequence derived from the control is shown. <bold>B</bold>: The sequence derived from patient shows a homozygous g.31812215T&#x0003e;G mutation.</p></caption><graphic xlink:href="mv-v17-1414-f6"/></fig><p>Improved splice site prediction for both intronic changes showed that the location of these changes is not present at a splice site and may not create splicing error in the PAX6 protein.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The genetic basis of coloboma remains elusive. Recent studies suggest that earlier developmental process in the eye are controlled by a complex network of transcriptional factors, cell cycle regulators, and diffusible signaling molecules [<xref ref-type="bibr" rid="r6">6</xref>]. Mutations in these genes may lead to ocular coloboma. It has been proposed that PAX6 acts as a transcriptional regulator of many other genes involved in ocular development. <italic>PAX6</italic> mutations have been identified in sporadic aniridia cases from different populations [<xref ref-type="bibr" rid="r17">17</xref>] as well as in familial aniridia cases [<xref ref-type="bibr" rid="r14">14</xref>-<xref ref-type="bibr" rid="r16">16</xref>]. In this study we have screened <italic>PAX6</italic> in irido-fundal coloboma patients and controls and we observed 3 changes (2 intronic changes and one synonymous/neutral change). However, no pathogenic <italic>PAX6</italic> mutation was identified in our patients.</p><p>Mutations in <italic>PAX2</italic> were identified in individuals with ocular coloboma in renal coloboma syndrome [<xref ref-type="bibr" rid="r24">24</xref>]. <italic>PAX2</italic> is a member of a multi-gene family containing a paired box domain that was identical in <italic>Drosophila</italic> and subsequently in vertebrates [<xref ref-type="bibr" rid="r25">25</xref>]. <italic>PAX2</italic> expression is critical for development of urogenital tract, central nervous system (CNS), inner ear, and optic nerve. Further studies suggest that <italic>PAX2</italic> mutations are not common in patients with isolated ocular coloboma and associated anomalies [<xref ref-type="bibr" rid="r26">26</xref>].</p><p>The absence of <italic>PAX6</italic> mutations in our study population suggests the involvement of other coloboma genes showed by Zhang et al. [<xref ref-type="bibr" rid="r27">27</xref>]. This study expands the SNP spectrum of <italic>PAX6</italic>, only rare variations which are not causative have been found. Since this is a pilot study in the north Indian population, our results should be confirmed in different populations by similar studies. However, the absence of <italic>PAX6</italic> mutations in selected population do not rule out the possibility of involvement of this gene in coloboma. Friling et al. [<xref ref-type="bibr" rid="r28">28</xref>] have shown the deletion of the whole gene (11p) in a patient with uveal colobomata. So there is still a possibility for <italic>PAX6</italic> to be involved in coloboma cases which can be detected by CGH array. As the frequency of the congenital blindness is more in Asian countries [<xref ref-type="bibr" rid="r18">18</xref>], where a majority of the population has vitamin A deficiency which is required for normal expression of several genes involved in ocular morphogenesis. Vitamin A is critical during eye development and optic fissure fails to close in vitamin A deficient embryos [<xref ref-type="bibr" rid="r29">29</xref>]. It has been reported that <italic>Pitx2</italic> expression is downregulated in vitamin A deficient embryos and this gene is required for optic fissure closure. Epidemiological evidences has shown the teratogenic effect of vitamin A deficiency during pregnancy. Thus screening of the candidate gene is required in large number of cases. Familial cases are required for determination of the underlying genetic loci accounting for this clinical phenotype which may lead to better understanding of disease pathogenesis in near future.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank the families of the patients for their co-operation. The authors also thank AIIMS for providing financial support.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000e9;mond-Gignac</surname><given-names>D</given-names></name><name><surname>Bitoun</surname><given-names>P</given-names></name><name><surname>Reis</surname><given-names>LM</given-names></name><name><surname>Copin</surname><given-names>H</given-names></name><name><surname>Murray</surname><given-names>JC</given-names></name><name><surname>Semina</surname><given-names>EV</given-names></name></person-group><article-title>Identification of dominant FOXE3 and PAX6 mutations in patients with congenital cataract and aniridia.</article-title><source>Mol Vis</source><year>2010</year><volume>16</volume><fpage>1705</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">20806047</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopal</surname><given-names>L</given-names></name></person-group><article-title>A clinical and optical coherence tomography study of choroidal colobomas.</article-title><source>Curr Opin Ophthalmol</source><year>2008</year><volume>19</volume><fpage>248</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">18408502</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>RL</given-names></name><name><surname>Altmann</surname><given-names>CR</given-names></name><name><surname>Lang</surname><given-names>RA</given-names></name><name><surname>Hemmati-Brivanlou</surname><given-names>A</given-names></name></person-group><article-title>Pax6 induces ectopic eyes in a vertebrate.</article-title><source>Development</source><year>1999</year><volume>126</volume><fpage>4213</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10477290</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunliffe</surname><given-names>HE</given-names></name><name><surname>McNoe</surname><given-names>LA</given-names></name><name><surname>Ward</surname><given-names>TA</given-names></name><name><surname>Devriendt</surname><given-names>K</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Eccles</surname><given-names>MR</given-names></name></person-group><article-title>The prevalence of PAX2 mutations in patients with isolated colobomas or colobomas associated with urogenital anomalies.</article-title><source>J Med Genet</source><year>1998</year><volume>35</volume><fpage>806</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9783702</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandona</surname><given-names>L</given-names></name><name><surname>Dandona</surname><given-names>R</given-names></name><name><surname>Shamanna</surname><given-names>BR</given-names></name><name><surname>Naduvilath</surname><given-names>TJ</given-names></name><name><surname>Rao</surname><given-names>GN</given-names></name></person-group><article-title>Developing a model to reduce blindness in India: The International Centre for Advancement of Rural Eye Care.</article-title><source>Indian J Ophthalmol</source><year>1998</year><volume>46</volume><fpage>263</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10218314</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>JA</given-names></name><name><surname>Reed</surname><given-names>RR</given-names></name></person-group><article-title>Role of Olf-1 and Pax-6 transcription factors in neurodevelopment.</article-title><source>J Neurosci</source><year>1996</year><volume>16</volume><fpage>5082</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8756438</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Glaser</surname><given-names>T</given-names></name><name><surname>Jepeal</surname><given-names>L</given-names></name><name><surname>Maas</surname><given-names>R</given-names></name></person-group><article-title>Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes.</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>8355</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">8132558</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehring</surname><given-names>WJ</given-names></name><name><surname>Ikeo</surname><given-names>K</given-names></name></person-group><article-title>Pax 6: mastering eye morphogenesis and eye evolution.</article-title><source>Trends Genet</source><year>1999</year><volume>15</volume><fpage>371</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10461206</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grindley</surname><given-names>JC</given-names></name><name><surname>Davidson</surname><given-names>DR</given-names></name><name><surname>Hill</surname><given-names>RE</given-names></name></person-group><article-title>The role of Pax-6 in eye and nasal development.</article-title><source>Development</source><year>1995</year><volume>121</volume><fpage>1433</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">7789273</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>IM</given-names></name></person-group><article-title>PAX6 and congenital eye malformations.</article-title><source>Pediatr Res</source><year>2003</year><volume>54</volume><fpage>791</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14561779</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>D</given-names></name><name><surname>Ewan</surname><given-names>K</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name></person-group><article-title>Molecular regulators involved in vertebrate eye development.</article-title><source>Mech Dev</source><year>1998</year><volume>76</volume><fpage>3</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">9767078</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>HP</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>QJ</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name></person-group><article-title>A novel mutation of the PAX6 gene in a Chinese family with aniridia Chinese.</article-title><comment/><source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</source><year>2010</year><volume>27</volume><fpage>376</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">20677140</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koroma</surname><given-names>BM</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Sundin</surname><given-names>OH</given-names></name></person-group><article-title>The Pax-6 homeobox gene is expressed throughout the corneal and conjunctival epithelia.</article-title><source>Invest Ophthalmol Vis Sci</source><year>1997</year><volume>38</volume><fpage>108</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9008636</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>O'Keefe</surname><given-names>M</given-names></name></person-group><article-title>Aniridia: current pathology and management.</article-title><source>Acta Ophthalmol</source><year>2008</year><volume>86</volume><fpage>708</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">18937825</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquardt</surname><given-names>T</given-names></name><name><surname>Ashery-Padan</surname><given-names>R</given-names></name><name><surname>Andrejewski</surname><given-names>N</given-names></name><name><surname>Scardigli</surname><given-names>R</given-names></name><name><surname>Guillemot</surname><given-names>F</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name></person-group><article-title>Pax6 is required for the multipotent state of retinal progenitor cells.</article-title><source>Cell</source><year>2001</year><volume>105</volume><fpage>43</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">11301001</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maumenee</surname><given-names>IH</given-names></name><name><surname>Mitchell</surname><given-names>TN</given-names></name></person-group><article-title>Colobomatous malformations of the eye.</article-title><source>Trans Am Ophthalmol Soc</source><year>1990</year><volume>88</volume><fpage>123</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">2095017</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosser</surname><given-names>J</given-names></name><name><surname>van Heyningen</surname><given-names>V</given-names></name></person-group><article-title>PAX6 mutations reviewed.</article-title><source>Hum Mutat</source><year>1998</year><volume>11</volume><fpage>93</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">9482572</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahi</surname><given-names>JS</given-names></name><name><surname>Sripathi</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>CE</given-names></name><name><surname>Foster</surname><given-names>A</given-names></name></person-group><article-title>Childhood blindness in India: causes in 1318 blind school students in nine states.</article-title><source>Eye</source><year>1995</year><volume>9</volume><fpage>545</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">8543070</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>MG</given-names></name><name><surname>Eeckman</surname><given-names>FH</given-names></name><name><surname>Kulp</surname><given-names>D</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name></person-group><article-title>Improved Splice Site Detection in Genie</article-title><source>J Comput Biol</source><year>1997</year><volume>4</volume><fpage>311</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9278062</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanyanusin</surname><given-names>P</given-names></name><name><surname>McNoe</surname><given-names>LA</given-names></name><name><surname>Sullivan</surname><given-names>MJ</given-names></name><name><surname>Weaver</surname><given-names>RG</given-names></name><name><surname>Eccles</surname><given-names>MR</given-names></name></person-group><article-title>Mutation of PAX2 in two siblings with renal-coloboma syndrome.</article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><fpage>2183</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8589702</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>C</given-names></name><name><surname>Alembik</surname><given-names>Y</given-names></name><name><surname>Dott</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>MP</given-names></name></person-group><article-title>Congenital eye malformations in 212,479 consecutive births.</article-title><source>Ann Genet</source><year>1997</year><volume>40</volume><fpage>122</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9259960</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>C</given-names></name><name><surname>Alembik</surname><given-names>Y</given-names></name><name><surname>Dott</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>MP</given-names></name></person-group><article-title>Epidemiology of congenital eye malformations in 131,760 consecutive births.</article-title><source>Ophthalmic Paediatr Genet</source><year>1992</year><volume>13</volume><fpage>179</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">1484696</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strachan</surname><given-names>T</given-names></name><name><surname>Read</surname><given-names>AP</given-names></name></person-group><article-title>PAX genes.</article-title><source>Curr Opin Genet Dev</source><year>1994</year><volume>4</volume><fpage>427</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">7919921</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>White</surname><given-names>IM</given-names></name><name><surname>Hanson</surname><given-names>IM</given-names></name></person-group><article-title>PAX6 mutations: genotype-phenotype correlations.</article-title><source>BMC Genet</source><year>2005</year><volume>6</volume><fpage>27</fpage><pub-id pub-id-type="pmid">15918896</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>C</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name></person-group><article-title>Pax-6, a murine paired box gene, is expressed in the developing CNS.</article-title><source>Development</source><year>1991</year><volume>113</volume><fpage>1435</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">1687460</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LM</given-names></name><name><surname>Ying</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Hao</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>ND</given-names></name></person-group><article-title>R240X mutation of the PAX6 gene in a Chinese family with congenital aniridia.</article-title><source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi.</source><year>2009</year><volume>26</volume><fpage>546</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19806579</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title>Mutational screening of 10 genes in Chinese patients with microphthalmia and/or coloboma.</article-title><source>Mol Vis</source><year>2009</year><volume>15</volume><fpage>2911</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20057906</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friling</surname><given-names>R</given-names></name><name><surname>Yassur</surname><given-names>Y</given-names></name><name><surname>Abeliovich</surname><given-names>D</given-names></name><name><surname>Biedner</surname><given-names>B</given-names></name><name><surname>Galil</surname><given-names>A</given-names></name><name><surname>Dagan</surname><given-names>J</given-names></name></person-group><article-title>Carmi, R. A complex chromosome translocation resulting in deletion 11p and associated with uveal colobomata.</article-title><source>Ophthalmic Genet</source><year>1995</year><volume>16</volume><fpage>71</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7493159</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>See</surname><given-names>AW</given-names></name><name><surname>Clagett-Dame</surname><given-names>M</given-names></name></person-group><article-title>The temporal requirement for vitamin A in the developing eye: mechanism of action in optic fissure closure and new roles for the vitamin in regulating cell proliferation and adhesion in the embryonic retina.</article-title><source>Dev Biol</source><year>2009</year><volume>325</volume><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">18955041</pub-id></element-citation></ref></ref-list></back></article>